1. Home
  2. FF vs LUNG Comparison

FF vs LUNG Comparison

Compare FF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FutureFuel Corp.

FF

FutureFuel Corp.

HOLD

Current Price

$3.41

Market Cap

141.5M

Sector

Industrials

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.54

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FF
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.5M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
FF
LUNG
Price
$3.41
$2.54
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
204.3K
1.1M
Earning Date
11-10-2025
11-12-2025
Dividend Yield
7.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$137,409,000.00
$91,664,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
15.59
52 Week Low
$3.09
$1.31
52 Week High
$5.78
$9.37

Technical Indicators

Market Signals
Indicator
FF
LUNG
Relative Strength Index (RSI) 50.22 71.32
Support Level $3.15 $1.96
Resistance Level $3.49 $1.74
Average True Range (ATR) 0.11 0.20
MACD 0.04 0.10
Stochastic Oscillator 77.92 91.13

Price Performance

Historical Comparison
FF
LUNG

About FF FutureFuel Corp.

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: